RxDoctor Payments Data

Kathleen Walsh, MD

Obstetrics & Gynecology · Wall Township, NJNPI 1851374045

Payments from drug & device makers

$2,443in general payments, 2019–2025

Across 129 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$496
  • Astellas Pharma US Inc$399
  • Bayer$302
  • Pacira Pharmaceuticals Incorporated$218
  • Mayne Pharma Commercial LLC$210
  • Sumitomo Pharma America, Inc.$136
  • plus $682 from 15 others

What the payments were for

  • Food & beverage$2,23291%
  • Education$2119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,443 in reported general payments places this provider in the 80th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

See all obstetrics & gynecology providers in New Jersey

Medicare billing

Part B allowed, 2024
$19,978
Medicare patients
229
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol97$12,932
PremarinEstrogens, Conjugated31$10,118
MyrbetriqMirabegron14$7,848
YuvafemEstradiol18$2,867
OsphenaOspemifene11$2,623
Raloxifene Hcl26$1,450
Estradiol (Twice Weekly)Estradiol13$835
ValacyclovirValacyclovir Hcl26$469
BalzivaNorethindrone-Ethin. Estradiol11$396
ProgesteroneProgesterone, Micronized17$352
Oxybutynin Chloride ErOxybutynin Chloride11$205
Metronidazole12$201
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet11$165
Clobetasol Propionate14$157
Alendronate Sodium26$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$23$10,11831 claims
Astellas Pharma US IncMyrbetriq$399$7,84814 claims
Duchesnay USA IncorporatedOsphena$15$2,62311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

Other obstetrics & gynecology in Wall Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →